 DUBLIN, Ireland, April 17, 2021 GLOBE NEWSWIRE -- Avadel Pharmaceuticals plc Nasdaq: AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate ON-SXB for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual AAN Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act PDUFA target date of October 15, 2021. 